Results 191 to 200 of about 200,531 (312)

Clinical and Economic Burden in Patients With Systemic Lupus Erythematosus During the First Year After Initiating Oral Corticosteroids: A Retrospective US Database Study. [PDF]

ACR Open Rheumatol, 2023
DerSarkissian M, Gu YM, Duh MS, Benson J, Huang SP, Averell C, Vu J, Wang MJ, Bell CF.   +8 more
europepmc   +1 more source

Estradiol replacement attenuates alendronate‐associated adverse effects on alveolar bone repair in ovariectomized rats

Journal of Periodontology, EarlyView.
Abstract Background Sodium alendronate (ALN) is widely used to treat postmenopausal osteoporosis, but both estrogen deficiency and antiresorptive therapy may impair alveolar bone repair after tooth extraction. A clinically relevant but insufficiently explored scenario involves estrogen‐deficient individuals receiving hormone replacement therapy (HRT ...
Pedro H. C. Isaias, Paulo G. B. Silva, Isabelly V. do Nascimento, Raul A. D. A. da Silva, Thayla M. do C. Sousa, Ana J. A. de de Vasconcelos, José V. M. Lemos, Fabrício B. Sousa, Ana P. N. N. Alves, Mário R. L. Mota   +9 more
wiley   +1 more source

Cumulative Dispensing of Oral Corticosteroids Over 12 Months in People with COPD. [PDF]

Int J Chron Obstruct Pulmon Dis
Burge AT, Cox NS, Dal Corso S, Jones AW, Faqih FM, Holland AE.   +5 more
europepmc   +1 more source

Delayed perforation after cold snare polypectomy for small colonic polyps in a patient receiving oral corticosteroids. [PDF]

DEN Open, 2023
Iwano H, Sato T, Ishii Y, Niki S, Sawaya R, Tamakawa S, Yamada M.   +6 more
europepmc   +1 more source

Symptom cluster profiles in adolescents with inflammatory bowel disease: Cross‐sectional study using ImproveCareNow data

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Sleep disturbance, pain, anxiety, depression, and fatigue are prevalent in adolescents and young adults with inflammatory bowel disease (IBD). These symptoms often present in co‐occurring sets, known as symptom clusters. We aimed to identify distinct symptom clusters and factors associated with symptom profiles in adolescents with ...
Caeli Malloy, Kurt Kroenke, Patrick O. Monahan, Susan M. Rawl, Steven J. Steiner, Wendy R. Trueblood Miller, for the ImproveCareNow Pediatric IBD Learning Health System   +6 more
wiley   +1 more source

Successful Remission of Nephrotic Syndrome Caused by IgA Nephropathy with Membranoproliferative Glomerulonephritis-pattern Lesion Treated by Cyclosporine and Oral Corticosteroids. [PDF]

Intern Med
Nakao Y, Mori Y, Kunieda J, Taguchi T, Mori K, Yamamura A, Naito S, Ando F, Mandai S, Iimori S, Susa K, Mori T, Ohashi K, Sohara E, Uchida S.   +14 more
europepmc   +1 more source

Atopic Eczema-Associated Fracture Risk and Oral Corticosteroids: A Population-Based Cohort Study. [PDF]

J Allergy Clin Immunol Pract, 2022
Matthewman J, Mansfield KE, Prieto-Alhambra D, Mulick AR, Smeeth L, Lowe KE, Silverwood RJ, Langan SM.   +7 more
europepmc   +1 more source

Multicenter experience using tofacitinib for treatment of refractory pediatric inflammatory bowel diseases in the United States

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Tofacitinib is a selective Janus kinase (JAK‐1) inhibitor approved for the treatment of ulcerative colitis (UC) in adults. Data is limited in the pediatric population. The aim of this study was to evaluate the efficacy of tofacitinib in pediatric inflammatory bowel disease (IBD).
Denise D. Young, Jennifer E. Murphy, Mallory Chavannes, Jennifer L. Dotson, Jeanne Tung, Erica Chang, Brad Pasternak, Erin Crawford, Nancy McGreal, Jonathan Moses, Sandra C. Kim   +10 more
wiley   +1 more source

Effects of Postoperative Oral Corticosteroids on Infection Rates in Upper Extremity Surgery. [PDF]

Hand (N Y)
Khabyeh-Hasbani N, Yan Y, Cohen JM, Abuqubo RZ, Koehler SM.   +4 more
europepmc   +1 more source

Safety and efficacy of weekly adalimumab 80 mg therapy in pediatric Crohn's disease

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Adalimumab is commonly used to induce and maintain remission in pediatric Crohn's disease (CD). However, data on the efficacy and safety of high‐dose adalimumab in this population are limited. This study aimed to evaluate the therapeutic effectiveness and safety of weekly high‐dose adalimumab (80 mg) in pediatric CD patients ...
Eyal Cohen‐Sela, Anat Yerushalmy‐Feler, Firas Rinawi, Esther Orlanski‐Meyer, Raouf Nassar, Ramit Magen‐Rimon, Yael Weintraub, Raanan Shamir, Dror S. Shouval, Manar Matar   +9 more
wiley   +1 more source